

厚生科学研究費補助金（医療機器開発推進研究事業）  
分担研究報告書

超音波を利用した siRNA 内包バブルリポソームのがん局所療法の臨床試験導入  
分担研究者 （株）ジーンケア研究所 古市 泰宏

研究要旨 これまでに我々は、ゲノム維持機構や細胞周期に関与する遺伝子群のなかから、そのサイレンシングが癌細胞特異的に細胞増殖の抑制をもたらす標的遺伝子の探索を行ってきた。その結果、RecQL1ヘリカーゼをはじめとするいくつかの遺伝子を、抗癌剤開発のための分子標的として見出した。これらの標的遺伝子について、ゼノグラフトモデルを用いて評価を行い、サイレンシングが腫瘍増殖抑制活性を示す有望な標的を得た。

A. 研究目的

これまでに我々は、ゲノム維持機構や細胞周期に関与する遺伝子群の中から、そのサイレンシングが、癌細胞特異的に細胞増殖の抑制をもたらす癌標的遺伝子の探索を行ってきた。その結果、RecQL1ヘリカーゼをはじめとするいくつかの遺伝子を抗癌剤開発の分子標的として見出した。これらの標的遺伝子について、そのサイレンシングが実際に抗腫瘍活性をもたらすかどうか、皮下担癌モデルをもちいて評価を行う。

B. 研究方法

これまでの研究で、正常組織および癌組織間で遺伝子発現の定量的な比較を行い、癌組織特異的に発現が亢進している遺伝子群を選抜するスクリーニングシステムを確立している。こ

こで選抜されてきた標的候補遺伝子に対して、siRNAをデザインし、RNA干渉に伴う細胞増殖抑制効果を測定・比較し、有望な標的を選抜する。

つづいて、これらの標的遺伝子のサイレンシングによる癌細胞増殖阻害の評価を、肺がん細胞株 A549 を皮下担がんしたゼノグラフトモデルを用いて行う。DDSとして、入手可能な *in vivo* 用のポリエチレンイミンを使用し、siRNA-ポリエチレンイミン複合体を局所投与し、それぞれの siRNA がもつ抗腫瘍活性について評価を行う。

（倫理面への配慮）

ヒト遺伝子DNAや動物を用いた研究ではないので、倫理面については問題ない。

C. 研究結果

標的遺伝子のサイレンシングがも

たらず癌細胞特異的な標的は、主として細胞周期干渉遺伝子であった。特にM期に関与する遺伝子群のサイレンシングは、細胞増殖に劇的な細胞死誘導活性を發揮した。このうち、正常細胞への影響が少ない数種のsiRNAを標的候補として選抜した。

実際の腫瘍に対する増殖阻害活性を評価するため、肺がん細胞株 A549 の皮下担がんモデルを使った。核酸量換算で 50  $\mu$ g の siRNA を、1日1回週2回を1クールとする3クルールの局所投与を行い、その抗腫瘍活性を評価した。送達手段 (DDS) としては、入手可能な *in vivo* jetPEI を用いた。

その結果、コントロール配列投与群に比較して、Eg5、Cdc5、KNTC2、RecQL1 のそれぞれの siRNA で 50~70% 程度の抗腫瘍活性を見出した。一方、PLK1 は、細胞系評価において、劇的な効果を見出していたが、マウスゼノグラフトモデルではほとんど抗腫瘍活性を見出せなかった。

#### D. 考察

今回、我々が見出した標的遺伝子は、細胞増殖に劇的な細胞死誘導活性を發揮したが、担癌モデル動物に対する抗腫瘍活性の程度は、様々であった。その理由としては、平面培養により増殖する細胞と、三次元増殖している細胞との性質上の違い、さらに siRNA の

送達効率の違いによるものと考えられる。今回見出した分子標的による抗腫瘍活性は、今後、試験数を増やし更なる詳細な検討が必要だと思われるが、有望であると思われる。

#### E. 結論

今回、我々が見出した分子標的は、ゼノグラフトモデルに対して効果的な抗腫瘍活性を示し、抗癌剤開発のための候補遺伝子として有望であると思われる。

#### F. 健康危険情報

#### G. 研究発表

##### 1. 論文発表

- 1) Futami K., Takagi M., Shimamoto A., Sugimoto M., Furuichi Y. Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase. *Biol & Pharm Bull*, 2007, 30 (10), 1958-1961
- 2) Futami K., Kumagai E., Makino H., Goto H., Takagi M., Shimamoto A., Furuichi Y. Induction of mitotic cell death in cancer cells by small interference RNA suppressing the expression of RecQL1 helicase. *Cancer Science*, 99 (1), 71-80, 2008

##### 2. 学会発表

二見和伸、熊谷栄美、牧野弘、伊藤千絵、古市泰宏、「RecQL1-siRNAの癌治療への応用」第17回アンチセンスシンポジウム、石川(2007)

H. 知的財産権の出願・登録状況

1. 特許取得
2. 実用新案登録
3. その他（出願特許）

厚生科学研究費補助金（医療機器開発推進研究事業）

分担研究報告書

超音波を利用した siRNA 内包バブルリポソームのがん局所療法の臨床試験導入

分担研究者 立花 克郎 福岡大学 医学部解剖学教室

研究要旨

標的バブルリポソームに最適化された低侵襲治療装置の開発

A. 研究目的

超音波エネルギーによる、生体作用、薬剤透過性亢進作用、細胞内遺伝子導入、など、既に多くの論文で最近報告されてきた。本研究の目的は、超小型の超音波発振セラミック技術を応用した超音波照射による遺伝子導入の検討およびその安全な低侵襲治療システムの確立にある。圧電素子に電圧を加えるとひずんで振動し、逆に振動を加えると電圧が発生する。今回、素材・大きさの異なる素子の振動数を変えることで発生する超音波エネルギー量を測定した。

次に電圧60Vにおける各素子（P6d-h3、P6d-h4、P6d-h5、P6d-H7、P6d-h8、P8d-h1、P8s-h1、P20d-h1）での超音波エネルギーを記録した。素子（素子の直径）：P6d-h3（6mm） P8d-h1（8mm）、P6d-h4（6mm） P8s-h1（8mm）、P6d-h5（6mm） P20d-h1（20mm）、P6d-H7（6mm）、P6d-h8（6mm）。そして、現在実験に使用されている素子（A、B、C、D）において40Vにおける各周波数での超音波エネルギーを記録した。

B. 研究方法

超音波発生装置 Sono Pore KTAC-4000を用い、Duty Rate:50%、Burst Rate:0.5Hzに設定した。素子P6d-h4を水槽内（水道水）に浮かべ、電圧を20～90Vまで10Vずつ増やしていき、それぞれの電圧において周波数を0.5～2.6MHzまで0.01MHzずつ増やしていき、超音波エネルギー（W）を記録した。

C. 研究結果

P6d-h4において電圧に比例し、超音波エネルギー量の増加を認めた。また、周波数0.59、0.7、0.85、1.24MHz付近にてピークをとり、周波数が増加するごとにピーク値も増加していった。1.24～2.2MHzの間ではエネルギー値はほぼ一定となった。1.6MHz以上で電圧50V以上では各電圧での超音波エネルギーは

ほぼ同じ推移をとり、電圧を上げててもエネルギー量の増加は見られなかった。

次に40Vにおいて各素子の周波数ごとの超音波エネルギー量を記録した。超音波エネルギー量は素子の大きさごとで異なった。大きさが6mmの素子はほぼP6d-h4と同様の結果であった。大きさが8mmの素子では周波数0.7、1.08、2.16、3.13MHz付近でピークとなり、周波数が増加するとピーク値はそれぞれ2.21、1、0.48、1.34Wとなり、3.13MHzで最も高値を示した。大きさが20mmの素子では周波数0.67、1.05、1.84MHzでピークとなり、周波数1.05MHzでは3.96Wと最高値を示した。

最後に現在、実験で使用されている素子A,B,C,Dにおいて電圧40Vでの超音波エネルギー量を記録した。素子Aは周波数を一定にしても超音波エネルギー量が一定せず、測定始めのエネルギー量をプロットしたが、他の素子B,C,Dと異なり、周波数の変化に相関したエネルギーの変化は見られなかった。素子B,C,Dは周波数0.7、1.09、1.43、2.16付近でピークとなり、特に周波数0.7付近で高値(それぞれ0.41、0.89、0.53)となった。

#### D. 考察

今回、各素子で電圧、周波数を変え、超音波エネルギーを測定した。素子の大きさ・材質によりエネルギー量が最高となる周波数が異なった。素子の大きさが

大きくなるほど、ピーク値が高値となった。素子Aは不良であると判断した。

#### E. 結論

新たな素子を実験に用いる際に、その素子における有効な超音波エネルギーを得ることができる最適な周波数を知ることが重要である。

#### F. 健康危険情報

なし

#### G. 研究発表

##### 1. 論文発表

1. Emoto M, Tachibana K, Iwasaki H, Kawarabayashi T. Antitumor effect of TNP-470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound. *Cancer Sci.* Jun;98(6):929-35. 2007
2. Tabuchi Y, Ando H, Takasaki I, Feril LB Jr, Zhao QL, Ogawa R, Kudo N, Tachibana K, Kondo T. Identification of genes responsive to low intensity pulsed ultrasound in a human leukemia cell line Molt-4. *Cancer Letters* 246:149-156. 2007

## 2. 学会発表

1. 超音波を用いたヒト神経線維腫細胞への Gamma Interferon Gene Transfection と増殖抑制効果の検討  
第3回ソノポーレーション研究会  
1.13 2007 福岡市
2. Sonotransfection as a potential alternative gene therapy method in treating pregnant women: a study using Gamma Interferon Gene against Neurofibroma  
The 23rd Fetus as a Patient  
International Congress 5.15-3.17  
2007 Manila, Philippines
3. 超音波血栓溶解療法  
日本超音波医学会第80回学術集会  
5.18-5.20 2007 鹿児島
4. Therapeutic Potentials of Low Intensity Ultrasound  
日本超音波医学会第80回学術集会  
5.18-5.20 2007 鹿児島
5. BR1 と BR14 による低浸襲性超音波の遺伝子導入効果の比較  
日本超音波医学会第80回学術集会  
5.18-5.20 2007 鹿児島
6. Enhanced gene transfer by echo contrast agents: comparison between BR1 and BR14 in vitro and in vivo

- American Society of Gene Therapy  
10th Annual Meeting 5.29-6.3 2007  
Washington
7. Interferon  $\beta$  Sonotransfection Inhibits Proliferation of Malignant Melanoma In-vivo  
7th international Symposium on Therapeutic Ultrasound 6.12-6.15  
2007 Seoul Korea
  8. 皮膚科領域における超音波の治療への応用  
ななくま 6-22 2007 福岡市
  9. Ultrasound-mediated Gene Transfection of Interferon  $\beta$  Inhibits Proliferation of Malignant Melanoma In-vivo  
平成19年度厚生省がん研究助成金(山崎班)第1回班会議 8.4 2007 東京
  10. HIFU (強力集束超音波治療法)  
第26回日本脳神経超音波学会  
7.8-7.10 2007 横浜
  11. Ultrasound-induced mechanical damage on cells enhanced by hypotonia-induced cell swelling  
19th International Congress on Acoustics 9.2-9.7 2007 Madrid Spain
  12. Effect of low-intensity ultrasound on human gastric carcinoma in nude mice

19th International Congress on  
Acoustics 9.2-9.7 2007 Madrid  
Spain

13. ヒトメラノーマ細胞への超音波照射による増殖抑制効果と超音波を用いた IFN $\beta$  と IFN $\gamma$  の遺伝子導入による増殖抑制効果の検討

平成19年度厚生省がん研究助成金(山崎班) 第2回班会議 10.30 2007  
東京

14. 超音波を用いたヒトメラノーマ細胞へのインターフェロン $\beta$  遺伝子の導入と増殖抑制効果の検討

第21回日本色素細胞学会学術大会  
12.8-12.9 2007 愛知県豊明市

15. The effect of cell killing by  
Ultrasound-Microbubble-Anticancer drug 第9回国際造影超音波シンポジウム 12.15-12.16 2007 大阪

#### H. 知的財産権の出願・登録状況

##### 1. 特許取得

1. Ultrasound catheter with  
utility lumen

United States

Patent:7,186,246

Bennett, et al. :March 6, 2007

##### 2. 実用新案登録

特になし

##### 3. その他

特になし

## 研究成果の刊行に関する一覧表レイアウト (参考)

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
T, Hamaguchi., K, Kato., <u>Y. Matsumura.</u> , et al.,	A Phase I and Pharmacokinetic Study of NK105, a Paclitaxel-incorporating Micellar Nanoparticle Formulation.	Brit J Cancer.	97	170-176	2007
<u>Y. Matsumura.</u>	Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles.	J Drug Targeting.	15	507-517	2007
K, Maekawa., <u>Y Matsumura.</u> , et al.	Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.	J Hum Genet.	52	804-819	2007
T, Nakajima., <u>Y. Matsumura.</u> , et al.	Synergistic antitumor activity of the novel SN-38 incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.	Int J Cancer	122	2148-2153	2008
S, Yajima., <u>Y Matsumura.</u> et al.	Expression profiling of fecal colonocytes for RNA-based screening of colorectal cancer.	Int J Oncol.	31	1029-37	2007
Y, Saito., <u>Y. Matsumura.</u> , et al.	Enhanced distribution of NK012 and prolonged sustained-release of SN-38 within tumors are the key strategic point for a hypovascular tumor.	Can Science.			in press.2008

M, Sumitomo., <u>Y. Matsumura.</u> , et al.	Novel SN-38-incorporated polymeric micelles, NK012, strongly suppresses renal cancer progression.	Cancer Res.	68	1631-1635	2008
Ryo Suzuki, Tomoko Takizawa, Yoichi Negishi, Naoki Utoguchi, Kaori Sawamura, Kumiko Tanaka, Eisuke Namai, Yusuke Oda, Yasuhiro Matsumura, <u>Kazuo Maruyama</u>	Tumor specific ultrasound enhanced gene transfer in vivo with novel liposomal bubbles;	J. Control. Release	125	137-144	2008
Ryo Suzuki, Tomoko Takizawa, Yoichi Negishi, Naoki Utoguchi, <u>Kazuo Maruyama</u>	Effective gene delivery with liposomal bubbles and ultrasound as novel non-viral system;	J. Drug Target.	15	531-537	2007
Aoi A, Watanabe Y, Mori S, <u>Kodama T.</u> , et al.	Herpes simplex virus thymidine kinase-mediated suicide gene therapy using nano/microbubbles and ultrasound	Ultrasound Med Biol	343	425-434	2008
Takahashi M, <u>Kodama T.</u> , et al.	Spinal gene transfer using ultrasound and microbubbles.	J Control Release	1172	267-272	2007
Futami K., Takagi M., Shimamoto A., Sugimoto M., <u>Furuichi Y.</u>	Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase.	Biol & Pharm Bull	30	1958-1961	2007
Futami K., Kumagai E., Makino H., Goto H., Takagi M., Shimamoto A., <u>Furuichi Y.</u>	Induction of mitotic cell death in cancer cells by small interference RNA suppressing the expression of RecQL1 helicase.	Cancer Science	99	71-80	2008
Sonoda S, <u>Tachibana K.</u> , Uchino E, Yamashita T, Sakoda K, Sonoda KH, Hisatomi T, Izumi Y, Sakamoto T.	Inhibition of melanoma by ultrasound-microbubble-aided drug delivery suggests membrane permeabilization.	Cancer Sci	98	929-35	2007
.Tabuchi Y. Ando H, Takasaki I, Feril LB Jr, Zhao QL, Ogawa R, Kudo N, <u>Tachibana K.</u> , Kondo T.	Identification of genes responsive to low intensity pulsed ultrasound in a human leukemia cell line Mol t-4.	Cancer Letters	246	149-156	2007

## A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

T Hamaguchi<sup>\*1</sup>, K Kato<sup>1</sup>, H Yasui<sup>1</sup>, C Morizane<sup>1</sup>, M Ikeda<sup>1</sup>, H Ueno<sup>1</sup>, K Muro<sup>1</sup>, Y Yamada<sup>1</sup>, T Okusaka<sup>1</sup>, K Shirao<sup>1</sup>, Y Shimada<sup>1</sup>, H Nakahama<sup>2</sup> and Y Matsumura<sup>3</sup>

<sup>1</sup>Department of Medicine National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; <sup>2</sup>Clinical Trial Coordinating Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; <sup>3</sup>Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan

This phase I study was designed to examine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), the recommended dose (RD) for phase II, and the pharmacokinetics of NK105, a new polymeric micelle carrier system for paclitaxel (PTX). NK105 was administered as a 1-h intravenous infusion every 3 weeks, without antiallergic premedication. The starting dose was 10 mg m<sup>-2</sup>, and the dose was escalated according to the accelerated titration method. Nineteen patients were recruited. The tumour types treated included pancreatic (*n* = 11), bile duct (*n* = 5), gastric (*n* = 2), and colonic (*n* = 1) cancers. Neutropenia was the most common haematological toxicity. A grade 3 fever developed in one patient given 180 mg m<sup>-2</sup>. No other grades 3 or 4 nonhaematological toxicities, including neuropathy, was observed during the entire study period. DLTs occurred in two patients given 180 mg m<sup>-2</sup> (grade 4 neutropenia lasting for more than 5 days). Thus, this dose was designated as the MTD. Grade 2 hypersensitivity reactions developed in only one patient given 180 mg m<sup>-2</sup>. A partial response was observed in one patient with pancreatic cancer. The maximum concentration (*C*<sub>max</sub>) and area under the concentration (AUC) of NK105 were dose dependent. The plasma AUC of NK105 at 150 mg m<sup>-2</sup> was approximately 15-fold higher than that of the conventional PTX formulation. NK105 was well tolerated, and the RD for the phase II study was determined to be 150 mg m<sup>-2</sup> every 3 weeks. The results of this phase I study warrant further clinical evaluation.

British Journal of Cancer (2007) 97, 170–176. doi:10.1038/sj.bjc.6603855 www.bjcancer.com

Published online 26 June 2007

© 2007 Cancer Research UK

**Keywords:** NK105; paclitaxel; polymer micelles; phase I study; DDS

Paclitaxel (PTX), an antimicrotubule agent, has a wide spectrum of antitumour activity including ovarian, breast, stomach, lung, and head and neck cancers (Rowinsky *et al*, 1990; Carney, 1996; Crown and O'Leary, 2000). The clinically used PTX preparation is a mixture of Cremophor EL and ethanol because of PTX's poor water solubility. However, the use of Cremophor EL is known to be associated with acute hypersensitivity reactions (Weiss *et al*, 1990; Rowinsky and Donehower, 1995; Kloover *et al*, 2004). Other PTX preparations that have been categorised as drug delivery systems (DDS) have also been developed. These preparations include Xyotax (polyglutamate-conjugated PTX; Singer *et al*, 2003; Boddy *et al*, 2005), Abraxane (PTX coated with albumin; Ibrahim *et al*, 2002; Deisai *et al*, 2003; Nyman *et al*, 2005), and Genexol-PM (a PTX micelle in which PTX has been simply solubilised; Kim *et al*, 2004). The common advantage shared by these formulations is that they are injectable intravenously without the mixture of Cremophor EL and ethanol. Among them, Abraxane has been approved for metastatic breast cancer by the Food and Drug Administration in the USA based on the results of a randomised phase 3 trial. In this trial, Abraxane demonstrated significantly higher response

rates, compared with standard PTX, and a significantly longer time to progression (Gradishar *et al*, 2005). In addition, the incidence of grade 4 neutropenia was significantly lower for Abraxane than for PTX. However, peripheral sensory neuropathy was more common in the arm (Gradishar *et al*, 2005).

NK105 is a PTX-incorporating 'core-shell-type' polymeric micellar nanoparticle formulation (Hamaguchi *et al*, 2005). This particle can be injected intravenously without the use of Cremophor EL or ethanol as a vehicle. Therefore, NK105 is expected to possess a clinical advantage similar to that of the above-mentioned PTX formulations. The difference between NK105 and the other PTX dosage forms is that NK105 is expected to yield a markedly higher plasma and tumour area under the concentration (AUC), compared with those for the other PTX formulations. Moreover, regarding the toxic profiles, the repeated administration of NK105 to rats at 7-day intervals produced significantly fewer toxic effects on peripheral nerves than free PTX. Macromolecular drugs, including NK105, have been developed based on the characteristic macroscopic features of solid tumours, such as hypervascularity, the presence of vascular permeability factors stimulating extravasation within cancer, and the suppressed lymphatic clearance of macromolecules. These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda *et al*, 2000; Duncan, 2003). The *in vivo*

\*Correspondence: Dr T Hamaguchi; E-mail: thamaguc@ncc.go.jp  
 Received 13 March 2007; revised 23 May 2007; accepted 23 May 2007;  
 published online 26 June 2007

antitumour activity of NK105 was significantly more potent than that of free PTX, probably because of enhanced tumour exposure through the EPR effect (Hamaguchi *et al*, 2005).

We conducted a phase I clinical trial using NK105 in patients with advanced solid tumours. The objectives of this trial were to determine the maximum tolerated dose (MTD), the phase II recommended dose (RD), and the pharmacokinetics of NK105.

## PATIENTS AND METHODS

The protocol and all materials were approved by the Institutional Review Board of the National Cancer Center, Tokyo. This study was conducted in compliance with the Good Clinical Practice Guidelines of the International Conference on Harmonization and the Declaration of Helsinki Principles. Written informed consent was obtained from all the patients.

### Therapeutic agent


NK105 was supplied by Nippon Kayaku Co. Ltd. (Tokyo, Japan) in 20-ml glass vials containing a dose equivalent to 30 mg of PTX. When reconstituted in 10 ml of 5% glucose solution and diluted with a total volume of 250 ml of 5% glucose, the reconstituted solution was stable for 24 h at room temperature. In our preclinical study, DLS and HPLC analysis showed that less than 2% of PTX incorporated in the micelles was released for 24 h at room temperature (data not shown).

Figure 1 shows the schematic structure of NK105, a PTX-entrapped polymeric micelle formulation. The NK105 polymers were constructed using polyethylene glycol (PEG) as the hydrophilic component and modified polyaspartate as the hydrophobic component. PEG is believed to form the outer shell of the micelle, producing a 'stealth' effect that enables NK105 to avoid being captured by the reticuloendothelial system.

The modified polyaspartate chain is hydrophobic and is believed to form the hydrophobic inner core of the micelles in aqueous media. The hydrophobic inner core enables NK105 to entrap a sufficient amount of PTX. NK105 has a diameter of about 90 nm (Hamaguchi *et al*, 2005).

### Patients

Patients with solid tumours refractory to conventional chemotherapy and for whom no effective therapy was available were eligible for enrolment in this study, provided that the following criteria were met: a histologically confirmed malignant tumour; a performance status of  $\leq 2$ ; an age of  $\geq 20$  and  $< 75$  years; a normal haematological profile (neutrophil count  $\geq 2000 \text{ mm}^{-3}$ , platelet count  $\geq 100\,000 \text{ mm}^{-3}$ , hemoglobin  $\geq 9 \text{ g dl}^{-1}$ ); normal hepatic function (total bilirubin level  $\leq 1.5 \text{ mg dl}^{-1}$ , AST and ALT  $\leq 2.5$



**Figure 1** Schematic structure of NK105. A polymeric micelle carrier of NK105 consists of a block copolymer of PEG (molecular weight of about 12,000) and modified polyaspartate. PEG is believed to be the outer shell of the micelle. PEG is believed to form the outer shell of the micelle. NK105 has a highly hydrophobic inner core, and therefore can entrap a sufficient amount of PTX.

times the upper normal limit); normal renal function (serum creatinine  $\leq 1.5 \text{ mg dl}^{-1}$ ); normal cardiac function (New York Heart Association (NYHA) classification of  $\leq 1$ ); normal pulmonary function ( $\text{PaO}_2 \geq 60 \text{ mm Hg}$ ); no chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin C) of the administration of NK105; and a life expectancy of more than 2 months. Patients with serious infections (including hepatitis B, hepatitis C, or HIV) were ineligible for enrolment in the study. Patients who had been previously treated with a taxane were excluded because of assessing neuropathy. Patients were also excluded if they were pregnant or lactating. Additionally, any patient whom the investigators considered ineligible was excluded.

### Drug administration

NK105 was dissolved in 5% glucose solution for injection at room temperature. NK105 was administered intravenously without in-line filtration and without premedication. NK105 solution was infused using an electric pump at a speed of  $250 \text{ ml h}^{-1}$ .

### Dosage and dose escalation

The starting dosage of NK105 was  $10 \text{ mg m}^{-2}$ , which is one-third of the toxic dose low in dogs. NK105 was administered once every 3 weeks, and the treatment was continued unless a severe adverse event or disease progression was observed. Dose escalation was performed according to the previously described accelerated titration method (Simon *et al*, 1997; Matsumura *et al*, 2004).

Toxicity was graded from 1 to 4 using the National Cancer Institute Common Toxicity Criteria (version 2.0). Inpatient dose escalation was not permitted. The MTD was defined as the level at which two out of six patients experienced dose-limiting toxicities (DLTs). The recommended dosage for a phase II trial was defined by the Efficacy and Safety Assessment Committee based on the safety, pharmacokinetics, and efficacy results of this trial. DLT was defined as grade 4 neutropenia lasting more than 5 days, a platelet count of less than  $25\,000 \mu\text{l}^{-1}$ , or grade 3 or higher non-haematological toxicity, with the exception of nausea, vomiting, appetite loss, and hypersensitivity.

### Pretreatment assessment and follow-up care

A complete medical history and physical examination, performance status evaluation, complete blood cell count (CBC), blood chemistry, urinalysis, electrocardiogram (ECG), and a computed tomography (CT) examination were performed in each patient. Other examinations were performed only in the presence of a specific clinical indication. Patients were physically examined every day until the second administration of NK105; CBC and blood chemistry tests were performed on day 3 and weekly thereafter. An ECG examination was repeated before each administration of NK105. Tumour marker levels were also measured before every administration. Tumour response was evaluated according to the Response Evaluation Criteria in Solid Tumors criteria (Therasse *et al*, 2000).

### Liquid chromatography/tandem mass spectrometry determination of PTX concentrations

The PTX concentrations determined in the present phase I study represented the total drug concentrations (both micelle-entrapped and released). It was difficult to measure released PTX and micelle-entrapped PTX separately, because the equilibrium between both forms could not keep constant during the separating procedure. PTX was extracted from human plasma (0.2 ml) or urine (0.5 ml) by deproteinisation with acetonitrile. The quantifications of PTX in plasma and urine were performed using liquid chromatography/tandem mass spectrometry. Reversed-phase column-switching

chromatography was conducted using an ODS column and detection was enabled by electrospray ionisation of positive mode.

### Pharmacokinetic analysis

The following pharmacokinetic parameters were calculated for each patient using a non-compartmental model using the WinNonlin Professional version 4.1 program (Pharsight Corporation, Mountain View, CA, USA). The maximum concentration ( $C_{max}$ ) was the maximum observed plasma concentration of PTX, and the time-to-the-maximum concentration ( $T_{max}$ ) was the time corresponding to  $C_{max}$ . The area under the concentration (AUC)-time curve from time zero up to the last quantifiable time point ( $AUC_{0-t}$ ) was calculated using the linear trapezoidal rule, and the area under the concentration-time curve from zero until infinity ( $AUC_{0-inf}$ ) was calculated as the sum of  $AUC_{0-t}$  and the extrapolated area under the zero moment curve from the last quantifiable time point to infinity calculated by dividing the plasma concentration of the last quantifiable time point (observed value) by the elimination rate constant. The half-life of the terminal phase ( $t_{1/2Z}$ ) was calculated as  $\log_e 2/\lambda_z$ , where  $\lambda_z$  is the elimination rate constant calculated from the terminal linear portion of the log of the concentration in plasma. Total clearance ( $CL_{tot}$ ), the volume of distribution at steady state ( $V_{ss}$ ), and renal clearance ( $CL_r$ ) were calculated using the following equations, where  $D$  is the dose and  $AUMC_{inf}$  the area under the first moment curve from time zero until infinity:

$$CL_{tot} = D/AUC_{inf}$$

$$V_{ss} = AUMC_{inf}/AUC_{inf} \times CL_{tot}$$

$$CL_r = \text{cumulative urinary excretion}/AUC_{inf} / \text{body surface area}$$

## RESULTS

### Patient characteristics

Nineteen eligible patients were recruited for the study (Table 1). All the patients had received chemotherapy before enrolment. Prior therapies ranged from 1 to 3 regimens of chemotherapy. None of the patients had received taxane chemotherapy. All the patients were included in the safety and response analyses.

### Dosing

Dosage escalation started at  $10 \text{ mg m}^{-2}$  and was increased up to  $180 \text{ mg m}^{-2}$ . In total, 73 administrations were performed in 19 patients. Eighteen patients received more than two administra-

**Table 1** Patient characteristics

Number of patients	19
Male/female	13/6
Age (years)	
Median	57
Range	43-72
ECOG PS	
Median	0
0	10
1	9
Prior treatment	
Chemotherapy regimens	
Median	1
Range	1-3

tions. The maximum number of treatments was 14 courses at  $150 \text{ mg m}^{-2}$ ; the average number of administrations at all levels was 3.8 courses. Up until  $80 \text{ mg m}^{-2}$ , grade 2 toxicity was not observed during the first course.

According to the original protocol, the dosage of NK105 should have been doubled for each escalation until grade 2 toxicity. However, the safety committee recommended that the dosage should be raised by 40% instead of 100% at  $110 \text{ mg m}^{-2}$  and that a modified Fibonacci escalation method should be implemented. Therefore, we recruited three patients at dosage level 5 ( $110 \text{ mg m}^{-2}$ ) and re-started the dose identification study using a modified Fibonacci method.

### Haematological toxicity

Significant myelosuppression was not observed up to level 4 ( $80 \text{ mg m}^{-2}$ ). At level 7 ( $180 \text{ mg m}^{-2}$ ), two out of five patients appeared to have acquired DLTs, namely grade 4 neutropenia lasting for more than 5 days. On the basis of these results,  $180 \text{ mg m}^{-2}$  was considered to be the MTD, with neutropenia as the DLT. Since a dosage of  $150 \text{ mg m}^{-2}$  was considered to be the recommended dosage for phase II studies, an additional four patients were enrolled at a dosage of  $150 \text{ mg m}^{-2}$ ; one patient developed DLT, namely grade 4 neutropenia lasting for more than 5 days (Table 2). During the entire period of this study, G-CSF was never used to rescue patients.

### Nonhaematological toxicity

The NK105 injection was generally uneventful and well tolerated in terms of nonhaematological toxicities (Table 2). Most of the toxicities were grade 1; none of the patients manifested grade 4 toxicity. A few patients developed a grade 1 elevation in AST or ALT, but these changes were transient. Pain or local toxicity in the area of the injection was not observed in any of the patients treated with NK105. No infusion-related reactions were observed; such reactions sometimes occur during liposomal drug administration. Patients were not premedicated with steroids or antihistamines. Only one patient at  $180 \text{ mg m}^{-2}$  developed grade 2 hypersensitivity. After the first course, the patient received premedication of hydrocortisone and did not develop such hypersensitivity after that. The other 18 patients did not experience any hypersensitivity during the study. Neuropathy occurred in a typical stocking/glove distribution and was manifested by numbness. Three patients at level 6 ( $150 \text{ mg m}^{-2}$ ) and three patients at level 7 ( $180 \text{ mg m}^{-2}$ ) experienced grade 1 neurotoxicity during 1 cycle. Of the four patients who received multicycle treatment more than five times, only three patients developed grade 2 neuropathy and the other patient developed grade 1 neuropathy. Even one patient who received 14 cycles of treatment experienced only grade 2 neuropathy.

### Pharmacokinetics

The plasma concentrations of PTX after the intravenous infusion of NK105 were determined in each of the patients enrolled at a dose of  $150 \text{ mg m}^{-2}$  (Figure 2A). The  $C_{max}$  (Figure 2B) and AUC (Figure 2C) increased as the doses were escalated from 10 to  $180 \text{ mg m}^{-2}$ . The pharmacokinetic parameters are summarised in Table 3. The  $t_{1/2Z}$  ranged from 7.0 to 13.2 h, and a slight tendency towards a dose-dependent extension of this parameter was observed. The  $CL_{tot}$  ranged from 280.9 to  $880.4 \text{ ml h}^{-1} \text{ m}^{-2}$ , and the  $V_{ss}$  ranged from 3668.9 to  $10400.3 \text{ ml m}^{-2}$ . Although these parameters were slightly reduced depending on the dose, linear pharmacokinetics was assumed to have been observed in the dose range from 10 to  $180 \text{ mg m}^{-2}$ . The AUC of NK105 at  $150 \text{ mg m}^{-2}$  (recommended phase II dose) was about 15-fold larger than that of conventional PTX at dose of  $210 \text{ mg m}^{-2}$  (conventional dose for a

**Table 2** Haematological and nonhaematological toxicities (cycle I and all cycles)

	10–110 mg m <sup>-2</sup> (n = 7) grade				150 mg m <sup>-2</sup> (n = 7) grade				180 mg m <sup>-2</sup> (n = 7) grade			
	1	2	3	4	1	2	3	4	1	2	3	4
<i>Cycle I</i>												
Leukopenia	2	0	2	0	1	5	1	0	1	1	3	0
Neutropenia	1	0	1	1	0	2	1	3 <sup>a</sup>	0	0	3	2 <sup>b</sup>
Thrombocytopenia	1	0	0	0	2	0	0	0	4	0	0	0
Hemoglobin	1	0	0	0	2	2	0	0	1	0	0	0
Neuropathy	0	0	0	0	3	0	0	0	3	0	0	0
Myalgia	1	0	0	0	3	0	0	0	2	1	0	0
Arthralgia	1	0	0	0	4	0	0	0	3	0	0	0
Hypersensitivity	0	0	0	0	0	0	0	0	0	1	0	0
Rash	1	0	0	0	1	3	0	0	4	0	0	0
Fatigue	1	0	0	0	5	0	0	0	4	0	0	0
Fever	2	0	0	0	2	0	0	0	1	0	1	0
Anorexia	0	0	0	0	3	0	0	0	1	0	0	0
Nausea	1	0	0	0	1	0	0	0	1	0	0	0
Stomatitis	0	0	0	0	1	0	0	0	1	0	0	0
Alopecia	3	0	—	—	5	0	—	—	5	0	—	—
<i>All cycles</i>												
Leukopenia	3	0	2	0	1	4	2	0	1	1	3	0
Neutropenia	1	0	1	1	1	1	1	4	0	0	3	2
Thrombocytopenia	1	0	0	0	3	0	0	0	4	0	0	0
Hemoglobin	1	0	0	0	1	5	0	0	1	0	0	0
Neuropathy	2	0	0	0	1	3	0	0	4	0	0	0
Myalgia	1	1	0	0	3	0	0	0	2	1	0	0
Arthralgia	2	0	0	0	4	0	0	0	3	0	0	0
Hypersensitivity	0	0	0	0	0	0	0	0	0	1	0	0
Rash	1	0	0	0	3	3	0	0	4	0	0	0
Fatigue	3	0	0	0	5	1	0	0	4	0	0	0
Fever	3	0	0	0	3	1	0	0	1	0	1	0
Anorexia	2	1	0	0	2	1	0	0	2	0	0	0
Nausea	1	0	0	0	1	0	0	0	2	0	0	0
Stomatitis	1	0	0	0	2	0	0	0	1	0	0	0
Alopecia	2	2	—	—	4	3	—	—	4	1	—	—

<sup>a</sup>One of three patients developed DLT, namely grade 4 neutropenia lasting for more than 5 days. <sup>b</sup>These two patients developed DLT, namely grade 4 neutropenia lasting for more than 5 days.

3-week regimen in Japanese patients) (Tamura *et al*, 1995). The  $V_{ss}$  and  $CL_{tot}$  of NK105 were significantly lower than those of conventional PTX.

The cumulative urinary excretion rates of PTX (0–73 h) after the administration of NK105 were 2.8–9.2%. These values were low, similar to those reported after the administration of conventional PTX (Tamura *et al*, 1995). The  $CL_r$  ranged from 11.7 to 66.4 ml h<sup>-1</sup> m<sup>-3</sup>, and was slightly decreased with the dose. Since the ratio of  $CL_r$  to  $CL_{tot}$  was 3–9%,  $CL_r$  hardly contributed to  $CL_{tot}$ .

### Therapeutic response

Six patients (two gastric, two bile duct, one colon, and one pancreatic) were evaluated as having had a stable disease for longer than 4 weeks at the time of the study's completion. A partial response was seen in a patient with metastatic pancreatic cancer who had been treated at 150 mg m<sup>-2</sup>, and in whom the size of the liver metastasis had decreased by more than 90%, compared to the baseline scan (Figure 3A). This patient had previously undergone treatment with gemcitabine. The antitumour response was maintained for nearly 1 year. In a patient with stomach cancer who was treated at 150 mg m<sup>-2</sup>, about 40% reduction was observed in a peritoneal metastasis, but a liver metastasis remained stable (Figure 3B).


### DISCUSSION

The observed toxicities of NK105 were similar to those expected for conventional PTX. The DLT was neutropenia. The recom-

mended phase II dose using a 3-week schedule was determined to be 150 mg m<sup>-2</sup>. This recommended dose of NK105 is less than that of conventional PTX (210 mg m<sup>-2</sup>). Since the plasma AUC of the recommended dose of NK105 was 15- to 20-fold higher than that of the recommended dose of conventional PTX (210 mg m<sup>-2</sup>), whether the so-called therapeutic window of NK105 is wider than that of conventional PTX should be determined in a future phases II or III trial, although the therapeutic window of NK105 appears to be wider than that of free PTX in mice experiments (Hamaguchi *et al*, 2005).

In general, haematological toxicity was mild and well managed in this trial. PTX is known to cause cumulative peripheral neuropathy resulting in the discontinuation of treatment with PTX. At a dose of 150 mg m<sup>-2</sup>, three out of seven patients experienced only grade 1 neuropathy during the first cycle. Since the patients enrolled in this trial had almost intractable cancer, such as pancreatic or stomach, a relatively small number of patients received multiple cycles of treatment. Therefore, NK105-related neurotoxicity could not be evaluated in this study. However, three out of four patients who received more than five cycles of treatment experienced transient grade 2 peripheral neuropathy, and other patient developed transient grade 1 peripheral neuropathy. Future phase II trials may clarify whether NK105 is less toxic in terms of peripheral neuropathy when compared with conventional PTX, Abraxane, and other PTX compounds. Another characteristic adverse effect of PTX is hypersensitivity, which may be mainly caused by Cremophor EL. Since NK105 is not formulated in a Cremophor EL-containing solvent, we presumed that hypersensitivity would be diminished.

Clinical Studies



**Figure 2** (A) Individual plasma concentrations of PTX in seven patients following 1-h intravenous infusion of NK105 at a dose of 150 mg m<sup>-2</sup>. (B) Relationships between dose and C<sub>max</sub>, and (C) between dose and AUC<sub>0-inf</sub> of PTX in patients following 1-h intravenous infusion of NK105. Regression analysis for dose vs C<sub>max</sub> was applied using all points except one patient at 80 mg m<sup>-2</sup> whose medication time became 11 min longer and one patient at 180 mg m<sup>-2</sup> who had medication discontinuation and steroid medication. (Plots were shown as open circle). Regression analysis for dose vs AUC<sub>0-inf</sub> was applied using all points except one patient who had medication discontinuation and steroid medication. (Plot was shown as open circle.) Relationships between dose and C<sub>max</sub> and AUC<sub>0-inf</sub> in patients following conventional PTX administration were plotted (closed square, see Tamura *et al*, 1995).


**Table 3** Pharmacokinetic parameters

	Dose (mg m <sup>-2</sup> )	n	C <sub>max</sub> (µg ml <sup>-1</sup> )	AUC <sub>0-inf</sub> (µg h ml <sup>-1</sup> )	t <sub>1/2</sub> (h)	CL <sub>tot</sub> (ml h <sup>-1</sup> m <sup>-2</sup> )	V <sub>ss</sub> (ml m <sup>-2</sup> )	UE <sup>a</sup> (%)	CL <sub>r</sub> (ml h m <sup>-2</sup> )
NK105	10	1	0.9797	11.4	9	880.4	10400.3	7.5	66.4
	20	1	2.8971	29.1	8.5	687.9	8027	8.6	59.4
	40	1	8.8334	93.9	13.2	426.1	5389.8	5.2	22
	80	1	18.4533	149.3	7	535.8	5875.8	4.7	25.3
	110	3	23.3924	232	9.7	483.3	5881.2	7.6	35.6
			±5.6325	±39.1	±1.6	±82.7	±1512.0	±1.7	±6.9
	150	7	40.1699	369.8	10.6	408.6	4527.1	5.3	21.6
			±5.5334	±35.2	±1.3	±37.3	±639.5	±1.5	±6.5
	180	4 <sup>b</sup>	45.6278	454.5	11.3	416.5	4983.4	5.9	23.7
			±8.6430	±119.1	±0.6	±104.7	±887.5	±1.4	±4.2

<sup>a</sup>UE, urinary excretion. <sup>b</sup>One patient at 180 mg m<sup>-2</sup> level was omitted from the calculation of summary pharmacokinetic parameters, as there was administrating interruption for developing allergic reactions.

Indeed, the results of this clinical trial show that NK105 can be administered safely as a short infusion (1 h) without the administration of antiallergic agents like dexamethasone and antihistamine, although one patient at 180 mg m<sup>-2</sup> developed transient grade 2 hypersensitivity at the first course. Therefore, NK105 may offer advantages in terms of safety and patient convenience and comfort.

The pharmacokinetic analysis of NK105 suggests that the distribution of PTX-incorporating micelles is mostly restricted to the plasma and, in part, to extracellular fluids in the body. This is consistent with data obtained in a preclinical study (Hamaguchi *et al*, 2005) showing that the distribution of NK105 in tissues is characterised by an EPR effect, similar to that of tumour and inflammatory lesions, or by the presence of a reticuloendothelial



**Figure 3** Serial CT scans. **(A)** A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of  $150 \text{ mg m}^{-2}$ . Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the baseline scan. The antitumour response was maintained for nearly 1 year. **(B)** A 64-year-old male with stomach cancer who was treated with NK105 at a dose level of  $150 \text{ mg m}^{-2}$ . Baseline scan (left panel) showing a peritoneal metastasis and liver metastasis. About 40% reduction (right panel) was observed in peritoneal metastasis, but not in the liver metastasis after fifth course.

**Table 4** Pharmacokinetic parameters

	Dose ( $\text{mg m}^{-2}$ )	n	$C_{\text{max}}$ ( $\mu\text{g ml}^{-1}$ )	$\text{AUC}_{0-\text{inf}}$ ( $\mu\text{g h}^{-1} \text{ml}^{-1}$ )	$t_{1/2}$ (h)	$\text{CL}_{\text{tot}}$ ( $\text{ml h}^{-1} \text{m}^{-2}$ )	$V_{\text{ss}}$ ( $\text{ml m}^{-2}$ )	UE (%)	$\text{CL}_r$ ( $\text{ml h}^{-1} \text{m}^{-2}$ )
NK105	150	7	40.1699 $\pm 5.5334$	369.8 $\pm 35.2$	10.6 $\pm 1.3$	408.6 $\pm 37.3$	4527.1 $\pm 639.5$	5.3 $\pm 1.5$	21.6 $\pm 6.5$
PTX	210	5	6.744 $\pm 2.733$	23.18 $\pm 10.66$	13.3 $\pm 1.5$	10740 $\pm 4860$	58 900 $\pm 24 700$	9.45 $\pm 3.76$	1020 $\pm 648$
XYOTAX <sup>a</sup>	233	4	NA	1583 $\pm 572$	120 $\pm 28$	276 $\pm 63$	6200 $\pm 2100$	NA	NA
Abraxane	300	5	13.52 $\pm 0.95$	17.61 $\pm 3.70$	14.6 $\pm 2.04$	17 700 $\pm 3894$	370 000 $\pm 85 100$	NA	NA
Genoxol-PM	300	3	3.107 $\pm 1.476$	11.58 $\pm 4.28$	11.4 $\pm 2.4$	29 300 $\pm 13 800$	NA	NA	NA

<sup>a</sup>Conjugated taxanes.

system. When compared with conventional PTX at a dose of  $210 \text{ mg m}^{-2}$  (conventional dose for a 3-week regimen in Japanese patients), NK105 at a dose of  $150 \text{ mg m}^{-2}$  (recommended phase II dose) exhibited more than 15-fold larger plasma AUC and a 26-fold lower  $\text{CL}_{\text{tot}}$ . The larger plasma AUC is consistent with the stability of the micelle formulation in plasma. The  $V_{\text{ss}}$  of NK105

was 13-fold lower than that of conventional PTX. This suggests that PTX may have a relatively lower distribution in normal tissue, including normal neural tissue, following NK105 administration. Regarding the drug distribution in tumours, nanoparticle drug carriers have been known to preferentially accumulate in tumour tissues utilising the EPR effect (Matsumura and Maeda, 1986;

Maeda et al, 2000; Duncan, 2003). We speculate that NK105 accumulates more in tumour tissues than free PTX, since NK105 is very stable in the circulation and exhibits a markedly higher plasma AUC than free PTX. Moreover, a polymeric micelle carrier system for a drug has the potential to enable the sustained release of the drug inside a tumour following the accumulation of micelles in the tumour tissue (Hamaguchi et al, 2005; Uchino et al, 2005; Koizumi et al, 2006). Regarding NK105 in particular, this sustained release may begin at a PTX-equivalent dose of  $<1 \mu\text{g ml}^{-1}$  (data not shown). Consequently, the released PTX is distributed throughout the tumour tissue where it kills the cancer cells directly.

In the present study, NK105 appeared to exhibit characteristic pharmacokinetics different from those of other PTX formulations including conventional PTX, Abraxane, Genexol-PM, and Xyotax. For example, previous clinical PK data at each phase II

recommended dose shown that plasma AUC and  $C_{\text{max}}$  were 11.58 and 3.1 in Genexol-PM (Table 4). The antitumour activities seen in two patients with intractable cancers are encouraging. In addition, we recently demonstrated in preclinical study that combined NK105 chemotherapy with radiation exerts a significantly more potent antitumour activity, compared with combined PTX therapy and radiation (Negishi et al, 2006). This data on NK105 justifies its continued clinical evaluation.

## ACKNOWLEDGEMENTS

We thank the patients who participated in this trial. We also thank Kaoru Shiina and Hiromi Orita for their secretarial assistance.

## REFERENCES

- Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH (2005) A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. *Clin Cancer Res* 11: 7834–7840
- Carney DN (1996) Chemotherapy in the management of patients with inoperable non-small cell lung cancer. *Semin Oncol* 23: 71–75
- Crown J, O'Leary M (2000) The taxanes: an update. *Lancet* 355: 1176–1178
- Deisai N, Trieu V, Yao R (2003) Evidence of greater antitumor activity of Cremophor-free nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol, role of a novel albumin transporter mechanism. *26th Annual San Antonio Breast Cancer Symposium* San Antonio, TX
- Duncan R (2003) The dawning era of polymer therapeutics. *Nat Rev Drug Discov* 2: 347–360
- Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol* 23: 7794–7803
- Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend *in vivo* antitumour activity and reduce the neurotoxicity of paclitaxel. *Br J Cancer* 92: 1240–1246
- Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. *Clin Cancer Res* 8: 1038–1044
- Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. *Clin Cancer Res* 10: 3708–3716
- Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. *Br J Cancer* 90: 304–305
- Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, Matsumura Y (2006) Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. *Cancer Res* 66: 10048–10056
- Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. *J Control Release* 65: 271–284
- Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. *Cancer Res* 46: 6387–6392
- Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N (2004) Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. *Br J Cancer* 91: 1775–1781
- Negishi T, Koizumi F, Uchino H, Kuroda J, Kawaguchi T, Naito S, Matsumura Y (2006) NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. *Br J Cancer* 95: 601–606
- Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. *J Clin Oncol* 23: 7785–7793
- Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). *New Engl J Med* 332: 1004–1014
- Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. *J Natl Cancer Inst* 82: 1247–1259
- Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. *J Natl Cancer Inst* 89: 1138–1147
- Singer JW, Baker B, De Vries P, Kumar A, Shaffer S, Vawter E, Bolton M, Garzone P (2003) Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. *Adv Exp Med Biol* 519: 81–99
- Tamura T, Sasaki Y, Nishiwaki Y, Saijo N (1995) Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. *Jpn J Cancer Res* 86: 1203–1209
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92: 205–216
- Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T (2005) Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. *Br J Cancer* 93: 678–687
- Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker Jr JR, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. *J Clin Oncol* 8: 1263–1268

## Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles

YASUHIRO MATSUMURA

*Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan*

### Abstract

Tumour-targeted delivery of therapeutic agents is a longstanding pharmacological goal to improve selectivity and Therapeutic Index. Most scientists have sought to use 'active' receptor-mediated tumour-targeting systems, however the 'passive' targeting afforded by the Enhanced Permeability and Retention (EPR) effects provides a versatile and non-saturable opportunity for tumour-selective delivery. Polymeric micelles are ideally suited to exploit the EPR effect, and they have been used for the delivery of a range of anticancer drugs in preclinical and clinical studies. Here I overview some of the more important approaches, assessing usefulness and seeking to identify the most promising ways to apply the phenomenon of passive targeting for improved clinical outcome.

**Keywords:** *Micelles, anticancer agent, EPR effect, clinical trial*

### Preface

Several problems of anticancer agents are recognized, such as their low therapeutic indices and limited efficacy due to the nonselective nature of their therapeutic targets and their inability to accumulate selectively in cancer tissues. Therefore, it would be desirable to develop modalities by which cytotoxic drugs can be selectively targeted to tumour tissues and allowed to act effectively on only the cancer cells in the tumor. The role of drug delivery systems (DDS) has drawn attention in this context. DDS could be used for active or passive targeting of tumor tissues. The former refers to the development of monoclonal antibodies directed against tumour-related molecules that allow targeting of the tumour, because of specific binding between the antibody and its antigen. However, the application of DDS using monoclonal antibodies is restricted to tumours expressing high levels of related antigens.

About a quarter of a century ago, after training as a surgeon, I started my career in the field of DDS under the supervision of Prof. Maeda. We made intensive efforts to ascertain the mechanism of accumulation

of macromolecules in solid tumours. Finally, we succeeded in publishing the first paper, in 1986, on the enhanced permeability and retention (EPR) effect (Matsumura and Maeda 1986). Passive targeting is based on this EPR effect. The EPR effect is based on the pathophysiological characteristics of solid tumour tissues: hypervascularity, incomplete vascular architecture, secretion of vascular permeability factors stimulating extravasation within cancer tissue, and absence of effective lymphatic drainage from tumours that impedes the efficient clearance of macromolecules accumulated in solid tumour tissues.

Several techniques to maximally use the EPR effect have been developed, e.g. modification of drug structures and development of drug carriers. Polymeric micelle-based anticancer drugs were originally developed by Prof. Kataoka et al. in late the 1980's or early 1990's (Yokoyama et al. 1990; 1991a, b, c; Kataoka et al. 1993). Polymeric micelles were expected to increase the accumulation of drugs in tumour tissues utilizing the EPR effect and to incorporate various kinds of drugs into the inner core by chemical conjugation or physical entrapment with relatively high stability. The size of the micelles

Correspondence: Y. Matsumura, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

can be controlled within the diameter range of 20–100 nm, to ensure that the micelles do not pass through normal vessel walls; therefore, a reduced incidence of the side effects of the drugs may be expected due to the decreased volume of distribution.

In this chapter, polymeric micelle systems for which clinical trials are now underway are reviewed.

### NK105, paclitaxel-incorporating micellar nanoparticle

Paclitaxel (PTX) is one of the most useful anticancer agents known for various cancers, including ovarian, breast and lung cancers (Carney 1996; Khayat et al. 2000). However, PTX has serious adverse effects, e.g. neutropenia and peripheral sensory neuropathy. In addition, anaphylaxis and other severe hypersensitive reactions have been reported to develop in 2–4% of patients receiving the drug even after premedication with antiallergic agents; these adverse reactions have been attributed to the mixture of Cremophor EL and ethanol which was used to solubilize PTX (Weiss et al. 1990; Rowinsky and Donehower 2003). Of the adverse reactions, neutropenia can be prevented or managed effectively by administering a granulocyte colony-stimulating factor. On the other hand, there are no effective therapies to prevent or reduce nerve damage which is associated with peripheral neuropathy caused by PTX; therefore, neurotoxicity constitutes a significant dose-limiting toxicity (DLT) of the drug (Rowinsky et al. 1993; Wasserheit et al. 1996).

#### Preparation and characterization of NK105

To construct NK105 micellar nanoparticles (Figure 1), block copolymers consisting of polyethylene glycol (PEG) and polyaspartate, so-called PEG-polyaspartate described previously (Yokoyama et al. 1990; 1991a, b, c; Kataoka et al. 1993), were used. PTX was incorporated into polymeric micelles formed by physical entrapment utilizing hydrophobic interactions between PTX and the block copolymer polyaspartate chain. After screening of many candidate substances, 4-phenyl-1-butanol was employed




Figure 1. Preparation and characterization of NK105. The micellar structure of NK105 PTX was incorporated into the inner core of the micelle.

for the chemical modification of the polyaspartate block to increase its hydrophobicity. Treating with a condensing agent, 1,3-diisopropylcarbodiimide, the half of carboxyl groups on the polyaspartate were esterified with 4-phenyl-1-butanol. Molecular weight of the polymers was determined to be approximately 20,000, (PEG block: 12,000; modified polyaspartate block: 8000). NK105 was prepared by facilitating the self-association of NK105 polymers and PTX. NK105 was obtained as a freeze-dried formulation and contained *ca.* 23% (w/w) of PTX, as determined by reversed-phase liquid-chromatography using an ODS column with mobile phase consisting of acetonitrile and water (9:11, v/v) and detection of ultraviolet absorbance at 227 nm. Finally, NK105, a PTX-incorporating polymeric micellar nanoparticle formulation with a single and narrow size distribution, was obtained. The weight-average diameter of the nanoparticles was approximately 85 nm ranging from 20 to 430 nm.

#### Pharmacokinetics and pharmacodynamics of NK105

Colon 26-bearing CDF1 mice were given a single iv injection of PTX 50 or 100 mg/kg, or of NK105 at an equivalent dose of PTX. Subsequently, the time-course changes in the plasma and tumour levels of PTX were determined in the PTX and NK105 administration groups; furthermore, the pharmacokinetic parameters of each group were also determined. NK105 exhibited slower clearance from the plasma than PTX, while NK105 was present in the plasma for up to 72 h after injection; PTX was not detected after 24 h or later of injection. The plasma concentration at 5 min ( $C_{5\text{min}}$ ) and the AUC of NK105 were 11- to 20-fold and 50- to 86-fold higher for NK105 than for PTX, respectively. Furthermore, the half-life at the terminal phase ( $t_{1/2\beta}$ ) was 4–6 times longer for NK105 than for PTX. The maximum concentration ( $C_{\text{max}}$ ) and AUC of NK105 in Colon 26 tumours were approximately 3 times and 25 times higher for NK105 than for PTX, respectively. NK105 continued to accumulate in the tumours until 72 h after injection. The tumour PTX concentration was higher than 10  $\mu\text{g/g}$  even at 72 h after the intravenous injection of NK105 50 and 100 mg/kg. By contrast, the tumour PTX concentrations at 72 h after the intravenous administration of free PTX 50 and 100 mg/kg were below detection limits and less than 0.1  $\mu\text{g/g}$ , respectively.

#### In vivo antitumour activity

BALB/c mice bearing s.c. HT-29 colon cancer tumours showed decreased tumour growth rates after the administration of PTX and NK105. However, NK105 exhibited superior antitumour activity as compared with PTX ( $P < 0.001$ ). The

antitumour activity of NK105 administered at a PTX-equivalent dose of 25 mg/kg was comparable to that obtained after the administration of free PTX 100 mg/kg. Tumour suppression by NK105 increased in a dose-dependent manner. Tumours disappeared after the first dosing to mice treated with NK105 at a PTX-equivalent dose of 100 mg/kg, and all mice remained tumour-free thereafter. In addition, less weight loss was induced in mice which were given NK105 100 mg/kg than in those which were given the same dose of free PTX.

### Neurotoxicity of PTX and NK105

Treatment with PTX has resulted in cumulative sensory-dominant peripheral neurotoxicity in humans, characterized clinically by numbness and/or paraesthesia of the extremities. Pathologically, axonal swelling, vesicular degeneration, and demyelination were observed. We, therefore, examined the effects of free PTX and NK105 using both electrophysiological and morphological methods.

Prior to drug administration, there were no significant differences in the amplitude of caudal sensory nerve action potential (caudal SNAP) between two drug administration groups. On day 6 after the last dosing (at week 6), the amplitude of the caudal SNAP in the control group increased in association with rat maturation. The amplitude was significantly smaller in the PTX group than in the control group ( $P < 0.01$ ), while the amplitude was significantly larger in the NK105 group than in the PTX group ( $P < 0.05$ ) and was comparable between the NK105 group and the control group (Figure 2). Histopathological examination of longitudinal paraffin-embedded sections of the sciatic nerve 5 days after the sixth weekly injection revealed degenerative changes. The NK105 administration group showed only a few degenerative myelinated fibers in contrast to the PTX administration




Figure 2. Effects of PTX or NK105 on the amplitude of rat caudal sensory nerve action potentials as examined 5 days after weekly injections for 6 weeks. Rats ( $n = 14$ ) were injected with NK105 or PTX at a PTX-equivalent dose of 7.5 mg/kg. About 5% glucose was also injected in the same manner to animals in the control group.

group which indicated markedly more numerous degenerative myelinated fibers.

### Clinical study

A phase I study was designed to determine maximum tolerated dose (MTD), DLTs, the recommended dose (RD) for phase II and the pharmacokinetics of NK105 (Kato et al.).

NK105 was administered by 1-hour intravenous infusion every 3 weeks without anti-allergic premedication. The starting dose was 10 mg PTX equivalent/m<sup>2</sup>, and dose escalated according to the accelerated titration method. To date, 17 patients (pts) have been treated at the following doses: 10 mg/m<sup>2</sup> ( $n = 1$ ); 20 mg/m<sup>2</sup> ( $n = 1$ ); 40 mg/m<sup>2</sup> ( $n = 1$ ); 80 mg/m<sup>2</sup> ( $n = 1$ ); 110 mg/m<sup>2</sup> ( $n = 3$ ); 150 mg/m<sup>2</sup> ( $n = 5$ ); 180 mg/m<sup>2</sup> ( $n = 5$ ). Tumor types treated have included: pancreatic ( $n = 9$ ), bile duct ( $n = 5$ ), gastric ( $n = 2$ ), and colon ( $n = 1$ ). Neutropenia has been the predominant hematological toxicity and grade 3 or 4 neutropenia was observed in pts treated at 110, 150 and 180 mg/m<sup>2</sup>. One patient at 180 mg/m<sup>2</sup> developed grade 3 fever. No other grade 3 or 4 non-hematological toxicity including neuropathies was observed. DLTs were observed in pts with at the 180 mg/m<sup>2</sup> (grade 4 neutropenia lasting for more than 5 days), which was determined as MTD. Allergic reactions were not observed in any of the patients except one patient at the 180 mg/m<sup>2</sup>. A partial response was observed in one pancreatic cancer pt who received more than 12 courses of NK105 (Figure 3). Despite of the long time usage, only grade 1 or 2 neuropathy was observed by modifying the dose or period of drug administration. Colon and gastric cancer pts experienced stable disease lasting 10 and 7 courses, respectively. The  $C_{max}$  and AUC of NK105 showed dose-dependent characteristics. The plasma AUC of NK105 at 180 mg/m<sup>2</sup> was approximately 30-fold higher than that of commonly-used paclitaxel formulation.

Accrual is ongoing at the 150 mg/m<sup>2</sup> dose level to determine RD. DLT was grade 4 neutropenia. NK105 generates prolonged systemic exposure to PTX in plasma. Tri-weekly 1-hour infusion of NK105 was feasible and well tolerated, with antitumor activity in pancreatic cancer pt. NK105 is planning to be evaluated in Phase II studies of patients with pancreatic, gastric, or ovarian cancer.

### NC-6004, cisplatin-incorporating micellar nanoparticle

Cisplatin [*cis*-dichlorodiammineplatinum (II): CDDP] is a key drug in the chemotherapy for cancers, including lung, gastrointestinal, and genitourinary cancer (Roth 1996; Horwich et al. 1997). However, we often find that it is necessary to




Figure 3. Serial CT scans. (A) A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of  $150 \text{ mg/m}^2$ . Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the baseline scan. The antitumor response was maintained for nearly 1 year.

discontinue treatment with CDDP due to its adverse reactions, e.g. nephrotoxicity and neurotoxicity, despite its persisting effects (Pinzani et al. 1994). Platinum analogues, e.g. carboplatin and oxaliplatin (Cleare et al. 1978), have been developed to date to overcome these CDDP-related disadvantages. Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al. 2003) and colon cancer (Cassidy et al. 2004). However, those regimens including CDDP are considered to constitute the standard treatment for lung cancer, stomach cancer, testicular cancer (Horwich et al. 1997), and urothelial cancer (Bellmunt et al. 1997). Therefore, the development of a DDS technology is anticipated, which would offer the better selective accumulation of CDDP into solid tumours while lessening its distribution into normal tissue.

#### Preparation and characterization of NC-6004

NC-6004 were prepared according to the slightly modified procedure reported by Nishiyama et al. (2003) (Figure 4). NC-6004 consists of PEG, a hydrophilic chain which constitutes the outer shell of the micelles, and the coordinate complex of poly(glutamic acid) (P(Glu)) and CDDP, a polymer-metal complex-forming chain which constitutes the inner core of the micelles. The molecular weight of PEG-P(Glu) as a sodium salt was approximately 18,000 (PEG: 12,000; P(Glu): 6000). The CDDP-incorporated polymeric micelles were clearly discriminated from typical micelles from amphiphilic block copolymers. The driving force of the formation of the

CDDP-incorporated micelles is the ligand substitution of platinum(II) atom from chloride to carboxylate in the side chain of P(Glu). The molar ratio of CDDP to the carboxyl groups in the copolymers was 0.71 (Nishiyama et al. 2003). A narrowly distributed size of polymeric micelles (30 nm) was confirmed by the dynamic light scattering (DLS) measurement. Also, the static light scattering (SLS) measurement revealed that the CDDP-loaded micelles showed no dissociation upon dilution and the CMC was less than  $5 \times 10^{-7}$ , suggesting remarkable stability compared with typical micelles from amphiphilic block copolymers (Nishiyama et al. 2003). It is assumed that the interpolymer cross-linking by Pt(II) atom might contribute to stabilization of the micellar structure.

The release rates of CDDP from NC-6004 were 19.6 and 47.8% at 24 and 96 h, respectively. In distilled water, furthermore, NC-6004 was stable without releasing cisplatin.

#### Pharmacokinetics and pharmacodynamics

FAAS could measure serum concentrations of platinum up to 48 h after i.v. injection of NC-6004 but could measure them only up to 4 h after i.v. injection of CDDP. NC-6004 showed a very long blood retention profile as compared with CDDP. The  $\text{AUC}_{0-t}$  and  $C_{\text{max}}$  values were significantly higher in animals given NC-6004 than in animals given CDDP, namely, 65-fold and 8-fold, respectively, ( $P < 0.001$  and  $0.001$ , respectively). Furthermore, the  $\text{CL}_{\text{tot}}$  and  $V_{\text{ss}}$  values were significantly lower in animals given NC-6004 than in animals given